Abstract 83P
Background
VG2025 is a non-attenuated HSV-1 Oncolytic virus (OV) with the payloads IL-12, IL-15, and IL-15Ra and a Carcinoembryonic Antigen (CEA) specific promoter for ICP27. Here, we reported a first-in-human, open-label study to evaluate the safety and efficacy of VG2025 in patients (pts) with advanced solid tumors that progressed after standard care, conducted in China.
Methods
3+3 Dose escalation design with 5 dose levels as intratumoral injections on days 1 and 15 of each 28-day cycle. Preliminary safety, efficacy (per RECIST v1.1), PK, viral shedding and the immune biomarkers were analyzed.
Results
The preliminary findings of this study were presented at ASCO 2023, here we present updated results of additional dose levels. As of Aug 8, 2023, 14 pts received doses of 1.0x10ˆ8 PFU (n=3), 2.0x10ˆ8 PFU (n=3), 4.0x10ˆ8 PFU (n=3), and 6.0x10ˆ8 PFU (n=5) of each cycle. The longest duration of treatment was more than 11 cycles and the treatment is still ongoing. There were 11 males and 3 females with a median age of 51.5 (41-74). 57.1% were PD(L)1 refractory, 28.6% had 2 prior lines of therapy, and 64.3% had 3 or more prior lines of therapy. The mean CEA level was 29.1 (normal range of 0-5 μg/L). Tumor types included 4 CRC, 2 Duodenal adenocarcinoma, 2 HCC, 2 Pancreatic cancer, 1 NSCLC, 1 ICC, 1 NEC and 1 Neuroendocrine cancer. No DLTs were observed. The incidence of TRAEs and Gr≥3 TRAEs were 92.9% and 50.0%, with fever being the most common TRAE. 4 pts had 7 SAEs, which were unrelated to VG2025. No TRAEs led to dose reduction or treatment discontinuation. No pts had positive viral shedding. Of 9 evaluable pts, the ORR was 22.2% (with 2 PRs: 1 ICC pt and 1 NEC pt) and the DCR was 77.8%. The PR pts showed meaningful reductions in CEA levels. Tumor shrinkage was also observed in non-injected lesions, demonstrating an abscopal effect. Nanostring analysis of paired biopsies from the PR pts demonstrated upregulation of integrin signaling pathway, antigen-presenting MHC (HLA-DQA1 and HLA-DRB1) and chemokine receptor (CMKLR1) genes, and activation of CD8+ T cells.
Conclusions
Monotherapy with VG2025 demonstrated activity with a well-tolerant safety profile in pts with advanced solid tumors that progressed after standard of care therapy.
Clinical trial identification
NCT05477849.
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Virogin Biotech Co., Ltd.
Funding
Has not received any funding.
Disclosure
Y. Shen, T. Liang: Financial Interests, Personal, Coordinating PI: Virogin. S. Rahimian, A. Qin, Y. Qiu, Q. Tan, R. Zhao: Financial Interests, Personal, Full or part-time Employment: Virogin. All other authors have declared no conflicts of interest.
Resources from the same session
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract